Dr. Natalie Callander
Claim this profileUniversity of Wisconsin Hospitals and Clinics
Expert in Multiple Myeloma
Studies Plasma Cell Neoplasm
11 reported clinical trials
20 drugs studied
Area of expertise
1Multiple Myeloma
Global LeaderStage III
Stage IV
HBcAb positive
2Plasma Cell Neoplasm
Stage III
Stage IV
HBcAb positive
Affiliated Hospitals
Clinical Trials Natalie Callander is currently running
Iberdomide Combo
for Multiple Myeloma
Similar to the paradigm established in other hematologic malignancies that are considered curable, the achievement of MRD(-) status is necessary for long term disease control in MM. The fact that the majority of patients remain MRD (+) after induction therapy and AHCT points to the opportunity to deploy novel agents with complementary mechanism of action and favorable toxicity profile to reach and maintain MRD (-) status. Given its favorable toxicity profile, the convenience of oral administration, and compelling single agent activity even in heavily pretreated MM, iberdomide is likely amenable to long term therapy in patients with high-risk of relapse/progression identified by the persistence of MRD(+). The investigators intend to develop combination(s) of iberdomide with other agents with complementary mechanism of action in the consolidation setting post AHCT in order to achieve and sustain MRD (-).
Recruiting3 awards Phase 1 & 214 criteria
Lenalidomide + Dexamethasone +/- Daratumumab
for Multiple Myeloma
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.
Recruiting2 awards Phase 312 criteria
More about Natalie Callander
Clinical Trial Related2 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Natalie Callander has experience with
- Lenalidomide
- Dexamethasone
- Daratumumab
- Bortezomib
- Carfilzomib
- Belantamab Mafodotin
Breakdown of trials Natalie Callander has run
Multiple Myeloma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Natalie Callander specialize in?
Natalie Callander focuses on Multiple Myeloma and Plasma Cell Neoplasm. In particular, much of their work with Multiple Myeloma has involved Stage III patients, or patients who are Stage IV.
Is Natalie Callander currently recruiting for clinical trials?
Yes, Natalie Callander is currently recruiting for 4 clinical trials in Madison Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Natalie Callander has studied deeply?
Yes, Natalie Callander has studied treatments such as Lenalidomide, Dexamethasone, Daratumumab.
What is the best way to schedule an appointment with Natalie Callander?
Apply for one of the trials that Natalie Callander is conducting.
What is the office address of Natalie Callander?
The office of Natalie Callander is located at: University of Wisconsin Hospitals and Clinics, Madison, Wisconsin 53792 United States. This is the address for their practice at the University of Wisconsin Hospitals and Clinics.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.